 |
|
 |
 |
SurgiLight,
Inc. (OTCBB: SRGL) |
|
SurgiLight,
Inc. Article
|
|
 |
PRESBYOPIC
TREATMENT BY LASER ASSISTED SCLERECTOMY
Carlos Vergés
MD, PhD
Professor of Ophthalmology
Institut Universitari Dexeus - Universidad Autónoma de
Barcelona
INTRODUCTION
Presbyopia is one of the outstanding challenges raised in
ophthalmology. Several methods attempt to correct presbyopia,
but none of them have achieved totally satisfactory results.
Following glasses and contact lenses, the traditional correction
systems, different surgical techniques were developed, some
modifying the anterior face of the cornea, the intraocular
lens, and the most recent technique that attempts to recover
the accommodation by means of
expanding the ciliary ring.
The sclera’s diameter enlargement in the first posterior
studies showed hopeful results, but as in most of the surgical
techniques, a regression occurred after the first months.
J.T. Lin, Ph.D. studying this phenomenon, arrived at the conclusion
that this regression was produced by the fibrosis in the treated
sclera spaces, recovering the ciliary ring to its initial
values.
To avoid the latter he proposed to perform sclera radial ablations,
with a sufficient wave thickness to stop the fibrosis. The
ablated space would fill in with tenon tissue, maintaining
its elasticity and, thus, keep the ciliary’s “belt”
expansion that follows these ablations.
MATERIALS AND METHODS
In our Department of Ophthalmology, we have performed
a study to evaluate this therapeutic hypothesis. Twenty-four
eyes of 12 consecutive patients diagnosed with presbyopia
underwent surgery performed with the OptiVision™ Er:YAG
laser of SurgiLight Inc., USA. The average
age was 49.3 years, ranging from 46 to 55 years, and with
presbyopia values between +1.0
and +2.5 Diopters. Eyes were accurately analyzed, examining
the visual acuity, IOP values, corneal topography, pachymetry,
biomicroscopy, fundoscopy, and campimetry. Postoperative follow-up
examinations were done on day 3, week 2, week 6, and months
3 and 6. After all preoperative tests were performed and written,
informed consent was obtained, the surgical
procedure was done under local anesthesia, subconjunctival
infiltration using 2% Lidocaine with adrenaline.
Topical anesthesia was instilled just prior to infiltration.
After making four fornix-based conjunctival flaps in the intermuscular
region and achieving hemostasis with bipolar cautery, four
pairs of radial ablative scleral excisions were made –
one pair in each quadrant. The length of each excision was
approximately 4.5 mm in length starting 0.5 mm from the limbus.
The separation between the paired excisions was approximately
2.5 mm. The depth of the grooves was about 75% of scleral
thickness using the blue hue of choroid as the endpoint indicator.
The peritomy sites were closed with bipolar forceps. The patient
was prescribed topical antibiotics and steroids along with
analgesic tablets.
RESULTS
The preoperative data show a median addition of 1.83
± 0.77 Diopters, visual acuity without correction around
J5, and changing to J1 with the addition. Far Figure 1. –
Laser assisted presbyopia sclerectomy (LAPS), post op 1 week.
Figure 2. LAPS – post op 3 weeks. Figure 3. LAPS –
post op 4 months. vision was better than 20/30 in all the
cases. At the 2-week postoperative visit, all the patients
presented improved near vision. All of them could read J3
or
better, and six patients, 50% of the group, increased to J1.
The best-corrected visual acuity was of 1.29 ± 0.52
Diopters. These values remained relatively stable during the
6-week, with slight variations at 3 and 6 month post-operative
visits. The far vision analysis showed a slight decrease (2
lines) at the first 72 hours postoperative, that was recovered
in all the cases.
The corneal topography did not show changes induced by the
technique, like in the visual field and corneal thickness.
Average reduction of postoperative IOP values were 2.6 mm
Hg. Fundoscopy and biomicroscopy intraocular exams did not
show evidence of changes.
All patients reported conjunctival hyperemia and signs of
irritation the first 48 hours. After this time, tolerance
was excellent.
DISCUSSION
Loss of accommodation that appears with aging seems to be
the cause of presbyopia. Different factors have been related
to this fact: atrophy of the ciliary’s muscle, lens
sclerosis, changes in the refractive index, balance alteration
of the cornea and crystalline aberrations,
loss of the lenticular capsule elasticity, increase of lens
size as other ectodermal tissues, etc.
Even though we still do not understand perfectly the physiopathologic
mechanism of presbyopia, the fact is that the ciliary ring
expansion would suppose a change in the relation between the
zonula-lens, producing a slight improvement of the accommodative
functioning, as it becomes evident in the Thornton, Fukasaku,
Schackar and Lin techniques. The principal
difference in the Lin technique (patented by SurgiLight) with
respect to the others, lies in using a laser, which performs
the sclera groove ablations, achieving the most important
result of avoiding the fibrosis and the regression of the
results.
Although this hypothesis has to be proven, there are studies
performed that showed good results, after more than a one
year follow up (Dr. Oscar Mallo, Argentina). Our studies showed
a significant improvement (P<0.001) in near vision without
correction, from J5 to J2, with an average of 1.29 corrected
diopters, maintaining these results during 6 months.
This data is certainly a very hopeful sign, and although more
studies are needed, this technique has proven to be simple,
only slightly traumatic, and with a low level of complications.
Our patients reported a high level of satisfaction. All of
them will be improving their vision in a short time, and their
far vision has not been affected, except in the first two
or three days postoperatively.
SurgiLight, Inc.
(OTCBB: SRGL)
12001 Science Drive, Suite 140, Orlando, FL 32826 •
Tel. (407) 482-4555 • Fax (407) 482-0505 • Website
www.surgilight.com • Email surgilightsales@aol.com
11-01
|
 |
|
 |
|
Disclaimer:
All material herein is information supplied by the company or
other sources believed to be reliable. The information contained
herein is not guaranteed by TheNewsGate.com to be accurate,
and should not be considered to be all-inclusive. The companies
that are discussed in this profile have approved the statements
made in this profile. This profile contains forward-looking
statements that involve risks and uncertainties. Statements
in this press release about the company's future expectations,
including: development of licensing and branding and all other
statements in this release, other than historical facts, are
"forward-looking statements" within the meaning of
section 27A of the Securities Act of 1933, section 21E of the
Securities Act of 1934, as that term is defined in the Private
Securities Reform Act of 1995. It is important to note that
actual results and ultimate corporate actions could differ materially
from those in such forward looking statements. Such "forward-looking
statements" are subject to risks and uncertainties set
forth from time to time in the Company's SEC reports. This material
is for informational purposes only and should not be construed
as an offer or solicitation of an offer to buy or sell securities.
TheNewsGate.com is not a licensed broker, broker dealer, market
marker, investment advisor, analyst or underwriter. Please consult
a broker before purchasing or selling any securities viewed
on http://TheNewsGate.com/ TheNewsGate.com's affiliates, officers,
directors and employees may have bought or may buy the shares
discussed in this profile and may profit in the event those
shares rise in value. TheNewsGate.com does not and will not
offer any opinion as to when others should sell; each investor
must make that decision based on his or her judgment of the
market.
|
|
| |
|
| |
|
|
| |
|
|
|
|
 |
|
 |
| |
|